Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
about
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaEmerging targeted therapies for melanoma treatment (review)Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateEffects of BRAF mutations and BRAF inhibition on immune responses to melanomaIn vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewSorafenib in melanoma.New therapeutic options in systemic treatment of advanced cutaneous melanoma.Vemurafenib in melanoma.Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS.Inhibition of angiogenesis for the treatment of metastatic melanoma.Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.Bone marrow-derived stem cell therapy for metastatic brain cancers.KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.Emerging growth factor receptor antagonists for the treatment of advanced melanoma.Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells
P2860
Q26824310-69FCA1C7-DFB9-4125-AC04-0039EBF6D215Q26829997-BD3C8B36-9BAD-49A8-98A6-CF3BFC6F3F96Q33887664-7F82415D-4F30-4744-AC79-98BF4228467BQ34646279-EB8668C5-C8D9-406D-9D03-AEC13236C2F8Q35506764-110D6AB6-6EE6-4A7E-AE51-1EDA1943B8F6Q36270115-6A801E78-B97F-4233-96B3-238E022F4AB5Q37990977-3CC4217D-D857-4DE6-B79B-B00086505583Q38065194-55348481-F7C9-48ED-9B12-8E2751EE25E7Q38101603-CFD361FE-7BA0-4358-B320-77F9EAE76850Q38101607-F86C277A-1EC3-46D5-924E-239FE09EF596Q38134302-397C76FF-C0EC-4504-8A56-187F8F1F9B75Q38196881-4AE76DAC-95D8-499E-91D9-9EE3ADA816F6Q38259683-EB508361-8290-43E6-AAF8-B7BD97289A32Q39078976-7C88D067-4757-41BB-82C6-C93D168CA7C2Q39340696-604AE923-83B5-4C93-8997-C7C9251240DBQ41859238-D8A107A3-32D8-4D66-BF7E-61D020B328F4Q51788677-98168139-C0D8-4195-9D13-21E3D3BC3279Q58712892-B888D3B7-CFF2-40AB-9854-A4311E1E16D2
P2860
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Sorafenib and dacarbazine as f ...... nd open-label phase II studies
@ast
Sorafenib and dacarbazine as f ...... nd open-label phase II studies
@en
type
label
Sorafenib and dacarbazine as f ...... nd open-label phase II studies
@ast
Sorafenib and dacarbazine as f ...... nd open-label phase II studies
@en
prefLabel
Sorafenib and dacarbazine as f ...... nd open-label phase II studies
@ast
Sorafenib and dacarbazine as f ...... nd open-label phase II studies
@en
P2093
P2860
P50
P356
P1476
Sorafenib and dacarbazine as f ...... nd open-label phase II studies
@en
P2093
A Affolter
C Chevreau
E Montegriffo
P D Nathan
P2860
P2888
P304
P356
10.1038/BJC.2011.257
P407
P577
2011-07-12T00:00:00Z